| Liraglutide: A Review of its Use in the Management of Type 2 Diabetes Mellitus. | |
| | |
MedLine Citation:
|
PMID: 22085389 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Liraglutide (Victoza®) is a subcutaneously administered glucagon-like peptide-1 (GLP-1) receptor agonist produced by recombinant DNA technology and used as an adjunct to diet and exercise in the treatment of adults with type 2 diabetes mellitus. This article reviews the clinical efficacy and tolerability of liraglutide in adults with type 2 diabetes, and provides a summary of its pharmacological properties. Recently published pharmacoeconomic studies of liraglutide are also reviewed. Administered subcutaneously, liraglutide (usually 1.2 or 1.8 mg once daily) generally produced greater improvements in glycaemic control than active comparators or placebo when administered as monotherapy or in combination with one or two oral antidiabetic drugs (OADs) to adults with type 2 diabetes in numerous randomized, controlled phase III trials. These included six trials in the LEAD trial programme that was designed to evaluate the efficacy and safety of liraglutide across a continuum of antihyperglycaemic management for patients with type 2 diabetes. Liraglutide was generally well tolerated, with a low risk of hypoglycaemia evident, in the phase III trials. The most common adverse events were gastrointestinal and included nausea and diarrhoea; most events were mild to moderate in severity and decreased in incidence over time. In conclusion, liraglutide has an important place in the management of adults with type 2 diabetes across a continuum of care. As well as providing effective glycaemic control, liraglutide improves pancreatic β-cell function and leads to bodyweight loss, thereby addressing some of the unmet needs of patients treated with traditional OADs. |
| | |
Authors:
|
Caroline M Perry |
Related Documents
:
|
21876979 - Metabolic effects of an entero-omentectomy in mildly obese type 2 diabetes mellitus pat... 19156619 - Helminth fauna of lycisalamandra billae (franzen & klewen) (luschan salamander) collect... 1101609 - Supraclavicular brachial plexus block with etidocaine without vasoconstrictor. prelimin... 2992399 - Acute monoarthritis associated with lipid liquid crystals. 22269009 - Hyperbaric oxygen therapy improves peripheral insulin sensitivity in humans. 21199269 - The effect of pramlintide acetate on glycemic control and weight in patients with type ... 17693419 - Diabetes, but not the metabolic syndrome, predicts the severity and extent of coronary ... 10921699 - Glucose-insulin-potassium solutions improve outcomes in diabetics who have coronary art... 19602559 - Peak growth hormone-releasing hormone-arginine-stimulated growth hormone is inversely a... |
Publication Detail:
|
Type: JOURNAL ARTICLE |
Journal Detail:
|
Title: Drugs Volume: 71 ISSN: 0012-6667 ISO Abbreviation: - Publication Date: 2011 Dec |
Date Detail:
|
Created Date: 2011-11-16 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7600076 Medline TA: Drugs Country: - |
Other Details:
|
Languages: ENG Pagination: 2347-2373 Citation Subset: - |
Affiliation:
|
Adis, a Wolters Kluwer Business, Auckland, New Zealand. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Eculizumab: A Review of its Use in Paroxysmal Nocturnal Haemoglobinuria.
Next Document: Low-Dose Topiramate Plus Sodium Divalproate for Positive Responders Intolerant to Full-Dose Monother...